𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Endoscopic horizontal partial laryngectomy by CO2 laser in the management of supraglottic squamous cell carcinoma

✍ Scribed by Francesco Bussu; Giovanni Almadori; Eugenio De Corso; Davide Rizzo; Mario Rigante; Claudio Parrilla; Vincenzo Valentini; Gaetano Paludetti


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
218 KB
Volume
31
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background.

The objective of this study was to evaluate the results of endoscopic horizontal supraglottic laryngectomy (EHSL) by CO~2~ laser.

Methods.

Between 1996 and 2005, 78 patients underwent a horizontal supraglottic laryngectomy operation (HSL) with an external approach and 70 underwent laser EHSL, as treatment for supraglottic laryngeal squamous cell carcinoma (LSCC). We evaluated oncological endpoints, comparing the external and the endoscopic approach.

Results.

Among patients primarily treated by EHSL, the 5‐year disease‐specific survival (DSS) was 89% (vs 80% in the external approach group). Statistical analysis did not reveal significant differences between the 2 groups as for survival nor for organ preservation. The most significant clinical predictor for DSS is neck relapse (p < .0001).

Conclusions.

This study confirms the effectiveness of laser EHSL in which oncological outcome is similar to the external approach and functional results are probably better. Neck management in this setting is fundamental to warrant the best survival. Β© 2009 Wiley Periodicals, Inc. Head Neck, 2009


πŸ“œ SIMILAR VOLUMES


IL-12- and IL-2-induced tumor regression
✍ Giovana R. Thomas; Zhong Chen; Ileana Enamorado; Caren Bancroft; Carter Van Waes πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 French βš– 313 KB πŸ‘ 2 views

Therapy with IL-12 or IL-2 induces tumor regression in only a few patients with head-and-neck squamous cell carcinoma (SCC), and the factors promoting responsiveness have not been well defined. In this study, we examined whether combined IL-12 and IL-2 therapy can induce tumor regression in a new mu